Trial record 4 of 5 for:    "Alkaptonuria"

Nitisinone (NTBC) In Different Age Groups Of Patients With Alkaptonuria

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
William Leo Nyhan, M.D., Ph.D., University of California, San Diego
ClinicalTrials.gov Identifier:
NCT01390077
First received: July 5, 2011
Last updated: November 8, 2013
Last verified: November 2013
  Purpose

Nitisinone is a potent inhibitor of the enzyme that catalyzes the formation of homogentisic acid, and should be an even more logical treatment for alkaptonuria than for tyrosinemia, for which it has been approved by the FDA.The objective of this research is to explore reported age related differences in toxicity of nitisinone and its pharmacokinetic underpinnings and to develop an optimal therapeutic requirement for a targeted population of presymptomatic patients. The additional effect of mixtures of amino acids excluding tyrosine will be explored to take advantage of protein synthesis to avoid elevations of tyrosine that would otherwise limit the optimal dosage of nitisinone. The study is designed to treat patients and find the optimal dosage of nitisinone to obtain maximal reduction in levels of homogentisic acid and maintain safe levels of tyrosine.

The long term objective in the target population of pre-symptomatic patients is the prevention of the characteristic effects on joint cartilage and tendons.


Condition Intervention Phase
Alkaptonuria
Drug: Nitisinone
Phase 2
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Nitisinone (NTBC) In Different Age Groups Of Patients With Alkaptonuria

Resource links provided by NLM:


Further study details as provided by University of California, San Diego:

Primary Outcome Measures:
  • Elimination or near elimination of homogentisic acid excretion [ Time Frame: 3-6 months ] [ Designated as safety issue: No ]
    Homogentisic acid will be measured in the urine of patients taking nitisinone. The goal is to eliminate homogentisic acid in the body thereby eliminating the damage done to joints and organs.


Secondary Outcome Measures:
  • Tyrosine levels [ Time Frame: three-six months ] [ Designated as safety issue: Yes ]
    The tyrosine levels will be monitored frequently to maintain safe levels while maximizing the decrease of homogentisic acid. The amino acid mixture employed will be Tyrex.


Estimated Enrollment: 15
Study Start Date: January 2011
Estimated Study Completion Date: June 2021
Estimated Primary Completion Date: January 2021 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Nitisinone
all subjects will receive open-label nitisinone
Drug: Nitisinone
Taken orally. Supplied as a 2mg tablet. The starting dose is 2 mg once daily.
Other Names:
  • Orfadin®,
  • NTBC

Detailed Description:

Study procedures are designed to:

  1. Develop a method for nitisinone measurement via tandem mass spectrometry (MS/MS).
  2. Determine whether differences between adult and children could be erased by employing a dosage regimen based on m2 of body surface area as opposed to per kg of body weight, as we have found in a recent study of dichloroacetate
  3. Determine optimal dosage for reduction of urinary levels of homogentisic acid and minimal elevation of plasma levels of tyrosine in the target population of pre-symptomatic patients.
  4. Determine optimal doses of Tyrex to prevent hypertyrosinemia and allow maximal reduction in homogentisic acid.

Baseline studies will include ophthalmologic examinations, echocardiogram, X-rays of all joints, MRI of selected joints when financially plausible; history and physical examinations with emphasis on joints and tendons. Ideally MRI will be repeated at 12 month intervals thereafter. Ophthalmologic exam, x-rays of the kidneys and prostate, and echocardiogram will be repeated approximately every 12 months, depending on the age of the subject and the nitisinone dose. Patients will be seen every 3 months for the first year, then at 6 month intervals to month 36. The timing of the visits may be altered in response to modifications of nitisinone and/or Tyrex doses.

Complete or near complete elimination of homogentisic acid excretion will be sought. Optimal NTBC dosage would be judged to yield plasma concentration of tyrosine less than 1000 mmol/L with the concomitant use of tyrosine free amino acid supplement. Dosage will be escalated or reduced dependent on evidence of accumulation of nitisinone and urinary levels of HGA. The maximum initial dose of nitisinone for adult and adolescent patients will be 0.2/mg/kg/day, younger patients may require a larger dose; the standard dose in hypertyrosinemia is 1mg/kg/day, which will be tentatively used as the maximum dose for all populations.

Patients will be asked to collect first morning or 12 hour urine collections for homogentisic acid and p-hydroxyphenyllactic acids and to monitor levels of tyrosine. Accumulation will be tested for by repeated studies after 3 months of treatment. Trough levels for nitisinone will be collected prior to and 5-7 days after dose increases and/or at months 6, 12, 18, 24 and every 12 months.

The SF-36 Health Status Survey, a two page quality of life questionnaire which asks about ADLs and emotional/social impacts of disease, will be completed by the patient or patient's parent at baseline and every six months.

At any point during the study if the plasma tyrosine level is greater than 900umol/L the amount of Tyrex or dietary protein intake may be modified, or the nitisinone dose may be decreased. Protein Saver blood spot cards, which can be done in the patient's home and mailed to our lab, will be given to the patients with instructions on blood collection to check the tyrosine level after 5-7 days of the drug/dietary modifications. These steps—the dietary modification with diet records if needed, addition or adjustment of Tyrex, adjustment of the nitisinone dose, and repeat tyrosine analysis—will be repeated as necessary.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Diagnosis of alkaptonuria with documented increased excretion of homogentisic acid
  2. Willing and able to provide written, signed informed consent, or age appropriate written assent and written informed consent by a legally authorized representative after the study has been explained, prior to any research-related procedures.
  3. Willing and able to be seen in the UCSD Clinical Center for Research or a satellite site for the study visits
  4. Possession of insurance coverage for standard of care procedures, clearly stated in the consent forms

Exclusion Criteria:

  1. Baseline tyrosine level above 250 mmol/mL
  2. Baseline serum creatinine, creatine kinase, or transaminases 2x upper limit of normal
  3. Baseline anemia or thrombocytopenia
  4. Current participation in another investigational medication trial.
  5. Pregnant or lactating women
  6. Current keratopathy, contact use or uncontrolled glaucoma
  7. History myocardial infarction or arrhythmia
  8. History of pulmonary insufficiency
  9. Psychiatric illness that may interfere with compliance or communication
  10. Current malignancy or hypertension
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01390077

Locations
United States, California
University of California San Diego
La Jolla, California, United States, 92093
Sponsors and Collaborators
University of California, San Diego
Investigators
Principal Investigator: William L Nyhan, MD, PhD University of California, San Diego
  More Information

Publications:
Responsible Party: William Leo Nyhan, M.D., Ph.D., Professor, University of California, San Diego
ClinicalTrials.gov Identifier: NCT01390077     History of Changes
Other Study ID Numbers: WLN02
Study First Received: July 5, 2011
Last Updated: November 8, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by University of California, San Diego:
homogentisic acid

Additional relevant MeSH terms:
Alkaptonuria
Ochronosis
Amino Acid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases
Pathologic Processes
Nitisinone
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 19, 2014